Reverse-Phase Chromatographic Determination and Intrinsic Stability Behavior of 5-[(4-Chlorophenoxy)Methyl]-1,3,4-Oxadiazole-2-Thiol

1. S. Z. Siddiqui, M. A. Abbasi, A. Rehman, M. Irshad, M. Ashraf, I. Ahmad, M. A. Lodhi, B. Mirza, H. Ismail, M. N. Akhtar and B. Shahzad, Synthesis, pharmacological evaluation, molecular docking and cytotoxicity studies on some N-substituted 5-[(4-chlorophenoxy)methyl]1,3,4-oxadiazole- 2yl-2-sulfanyl acetamides, Indo. Am. J. Pharm. Res. 4 (2014) 3603-3617.Search in Google Scholar

2. C. S. de Oliveira, B. F. Lira, J. M. Barbosa-Filho, J. G. F. Lorenzo and P. F. de Athayde-Filho, Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: A review of the literature from 2000-2012, Molecules 17 (2012) 10192-10231; https//doi.org/10.3390/molecules17091019210.3390/molecules170910192Search in Google Scholar

3. A. Savarino, A historical sketch of the discovery and development of HIV-1 integrase inhibitors, Expert Opin. Investig. Drugs 15 (2004) 1507-1522; https//doi.org/10.1517/13543784.15.12.150710.1517/13543784.15.12.1507Search in Google Scholar

4. E. D. Chrysina, M. N. Kosmopoulou, C. Tiraidis, R. Kardakaris, N. Bischler, D. D. Leonidas, Z. Hadady, L. Somsak, T. Docsa, P. Gergely and N. G. Oikonomakos, Kinetic and crystallographic studies on 2-(β-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site, Protein Sci. 14 (2005) 873-888; https//doi.org/10.1110/ps.04121610510.1110/ps.041216105Search in Google Scholar

5. N. D. James and J. W. Growcott, Zibotentan, Drugs Fut. 34 (2009) 624-633; https//doi.org/10.1358/ dof.2009.034.08.140020210.1358/dof.2009.34.8.1400202Search in Google Scholar

6. R. R. Somani and P. Y. Shirodkar, Oxadiazole: A biologically important heterocycle, Pharma Chem. 1 (2009) 130-140.Search in Google Scholar

7. N. Shehzadi, K. Hussain, M. Islam, N. I. Bukhari, M. T. Khan, M. Salman, S. Z. Siddiqui, A. Rehman and M. A. Abbasi, In silico drug-qualifying parameters of 5-[(4-chlorophenoxy)methyl]-1,3,4- oxadiazole-2-thiol, Lat. Am. J. Pharm. 35 (2016) 1991-1997.Search in Google Scholar

8. Center for Drug Evaluation and Research (CDER), Reviewer Guidance: Validation of Chromatographic Methods, Rockville, MD, 1994; http://www.fda.gov/downloads/Drugs/.../Guidances/UCM134409.pdf; last access date March 10, 2018.Search in Google Scholar

9. Food and Drug Administration (FDA), Guidance for Industry, Analytical Procedures and Methods Validation: Chemistry, Manufacturing and Controls Documentation, in Draft Guidance, Rockville, MD, 2000.Search in Google Scholar

10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Nov. 1996, Geneva, Nov. 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf; last access date March 10, 2018.Search in Google Scholar

11. S. Singh and M. Bakshi, Stress test to determine inherent stability of drugs, Pharm. Technol. 4 (2000) 1-14.Search in Google Scholar

12. M. Bakshi, B. Singh, A. Singh and S. Singh, The ICH guidance in practice: stress degradation studies on ornidazole and development of a validated stability-indicating assay, J. Pharm. Biomed. Anal. 26 (2001) 891-897; https://doi.org/10.1016/S0731-7085(01)00475-710.1016/S0731-7085(01)00475-7Search in Google Scholar

13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Stability Testing of New Drug Substances and Products ICH Q1A (R2), Current Step 4 version, Sep 1992, Geneva, Feb 2003; https:// www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf; last access date March 9, 2018.Search in Google Scholar

14. K. K. Hotha, S. P. K. Reddy, V. K. Raju and L. K. Ravindranath, Forced degradation studies: Practical approach-overview of regulatory guidance and literature for the drug products and drug substances, Int. Res. J. Pharm. 4 (2013) 78-85.10.7897/2230-8407.04517Search in Google Scholar

15. J. J. Pignatello, Dark and photoassisted iron(3+)-catalyzed degradation of chlorophenoxy herbicides by hydrogen peroxide, Environ. Sci. Technol. 26 (1992) 944-951; https//doi.org/10.1021/ es00029a01210.1021/es00029a012Search in Google Scholar

16. Z. D. Okram, B. Kanakapura, R. P. Jagannathamurthy and V. K. Basavaiah, Development of a simple UV-spectrophotometric method for the determination of lansoprazole and study of its degradation profile, Quím. Nova 35 (2012) 386-391; https://doi.org/10.1590/S0100-4042201200020002710.1590/S0100-40422012000200027Search in Google Scholar

17. K. L. Maier, E. Matejkva, H. Hinze, L. Leuschel, H. Weber and I. Beck-Speier, Different selectivities of oxidants during oxidation of methionine residues in the α-1-proteinase inhibitor, FEBS Lett. 250 (1989) 221-226.10.1016/0014-5793(89)80725-2Search in Google Scholar

18. C. M. Maciolek, B. Ma, K. Menzel, S. Laliberte, K. Bateman, P. Krolikowski and C. R. Gibson, Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor, Drug Metab. Dispos. 39 (2011) 763-770; https://doi.org/10.1124/dmd.110.03736610.1124/dmd.110.03736621325431Search in Google Scholar

19. A. Corma, T. Ródenas and M. J. Sabater, Aerobic oxidation of thiols to disulfides by heterogeneous gold catalysts, Chem. Sci. 3 (2012) 398-404; http://doi.org/10.1039/C1SC00466B10.1039/C1SC00466BSearch in Google Scholar

20. R. Kumar and S. L. Khokara, Chemistry and common synthetic route of 1,3,4-oxadiazole: an important heterocyclic moiety in medicinal chemistry, Int. J. Inst. Pharm. Life Sci. 2 (2005) 224-230.Search in Google Scholar